MediWound

MDWD

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

MediWound is an Israeli biotechnology company that makes treatments for serious wounds and burns. Its main product is NexoBrid, an enzyme-based gel that removes dead or damaged tissue from severe burn wounds without surgery. The company sells to hospitals and burn centers, primarily in the United States and Europe, and NexoBrid is also stockpiled by the U.S. government for use in mass casualty events.

MediWound earns revenue through product sales of NexoBrid and through government contracts, including a significant supply agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The company is small, with a market cap around $200 million, and its main competitive advantage is that NexoBrid uses a unique pineapple-derived enzyme complex that has no direct equivalent on the market. However, the company is currently losing money at a significant rate, and its key risk is whether it can grow commercial adoption of NexoBrid fast enough to reach profitability before needing additional funding.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-45.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+53.7% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

25.5%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~11 months

$36M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

MediWound has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

10.9%

Thin — 10.9% gross margin

Profit after running costs

Operating Margin

-305.9%

Losing money on operations — -305.9%

Return on the money invested

ROCE

-86.9%

Weak — -86.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-40.3%

Shrinking sales (-40.3% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-239.3%

Burning cash (-239.3%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.03

Conservative — low debt load (0.03)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial